REFERENCES
- Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage
cells and regression of lymphoma in a patient treated with autologous
T cells genetically engineered to recognize CD19. Blood.
2010;116(20):4099-4102. doi:10.1182/blood-2010-04-281931
- Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells
for sustained remissions in leukemia. N Engl J Med.
2014;371(16):1507-1517. doi:10.1056/NEJMoa1407222
- Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in Adult
Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med.
2019;380(1):45-56. doi:10.1056/NEJMoa1804980
- Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in Children
and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med.
2018;378(5):439-448. doi:10.1056/NEJMoa1709866
- Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis
and management of cytokine release syndrome. Blood.
2014;124(2):188-195. doi:10.1182/blood-2014-05-552729
- Schuster SJ, Maziarz RT, Rusch ES, et al. Grading and management of
cytokine release syndrome in patients treated with tisagenlecleucel in
the JULIET trial. Blood Adv. 2020;4(7):1432-1439.
doi:10.1182/bloodadvances.2019001304
- Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor
T-cell therapy - assessment and management of toxicities. Nat Rev Clin
Oncol. 2018;15(1):47-62. doi:10.1038/nrclinonc.2017.148
- Sandler RD, Tattersall RS, Schoemans H, et al. Diagnosis and
Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy
in Adults; A Review of the Literature and a Survey of Practice Within
EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP)
and Transplant Complications Working Party (TCWP). Front Immunol.
2020; 11:524. doi:10.3389/fimmu.2020.00524
- Lehmberg K, Nichols KE, Henter JI, et al. Consensus recommendations
for the diagnosis and management of hemophagocytic lymphohistiocytosis
associated with malignancies. Haematologica. 2015;100(8):997-1004.
doi: 10.3324/haematol.2015.123562.
- Henter JI, Horne A, Aricó M, et al. HLH-2004: Diagnostic and
therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr
Blood Cancer. 2007;48(2):124-31. doi: 10.1002/pbc.21039.
- Fardet L, Galicier L, Lambotte O, et al. Development and validation of
the HScore, a score for the diagnosis of reactive hemophagocytic
syndrome. Arthritis Rheumatol. 2014;66(9):2613-20. doi:
10.1002/art.38690.
- Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells
for sustained remissions in leukemia. N Engl J Med. 2014 Oct
16;371(16):1507-17. doi: 10.1056/NEJMoa1407222.
- Yamamoto S, Matsumoto SI, Goto A, et al. Quantitative PCR methodology
with a volume-based unit for the sophisticated cellular kinetic
evaluation of chimeric antigen receptor T cells. Sci Rep. 2020 Oct
21;10(1):17884. doi: 10.1038/s41598-020-74927-8.
- Turtle CJ, Hanafi LA, Berger C, et al. CD19 CAR-T cells of defined
CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest.
2016 Jun 1;126(6):2123-38. doi: 10.1172/JCI85309.
- Demaret J, Varlet P, Trauet J, et al. Monitoring CAR T-cells using
flow cytometry. Cytometry B Clin Cytom. 2021 Mar;100(2):218-224. doi:
10.1002/cyto.b.21941.
- La Rosée P. Treatment of hemophagocytic lymphohistiocytosis in adults.
Hematology Am Soc Hematol Educ Program. 2015;2015:190-6. doi:
10.1182/asheducation-2015.1.190.
- Wohlfarth P, Agis H, Gualdoni GA, et al. Interleukin 1 Receptor
Antagonist Anakinra, Intravenous Immunoglobulin, and Corticosteroids
in the Management of Critically Ill Adult Patients With Hemophagocytic
Lymphohistiocytosis. J Intensive Care Med. 2019;34(9):723-731. doi:
10.1177/0885066617711386.
- Strati P, Ahmed S, Kebriaei P, et al. Clinical efficacy of anakinra to
mitigate CAR T-cell therapy-associated toxicity in large B-cell
lymphoma. Blood Adv. 2020;4(13):3123-3127. doi:
10.1182/bloodadvances.2020002328.
- Major A, Collins J, Craney C, et al. Management of hemophagocytic
lymphohistiocytosis (HLH) associated with chimeric antigen receptor
T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative
case and review of the literature. Leuk Lymphoma. 2021 :1-7. doi:
10.1080/10428194.2021.1881507.
- ClinicalTrials.gov Identifier: NCT03311854; De Benedetti et al. (EULAR
2019).
- Locatelli F, Jordan MB, Allen C, et al. Emapalumab in Children with
Primary Hemophagocytic Lymphohistiocytosis. N Engl J Med. 2020 May
7;382(19):1811-1822. doi: 10.1056/NEJMoa1911326.
- Vallurupalli M, Berliner N. Emapalumab for the treatment of
relapsed/refractory hemophagocytic lymphohistiocytosis. Blood. 2019
Nov 21;134(21):1783-1786. doi: 10.1182/blood.2019002289.